BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24486603)

  • 1. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
    Nishio S; Ushijima K; Yamaguchi T; Sasajima Y; Tsuda H; Kasamatsu T; Kage M; Ono M; Kuwano M; Kamura T
    Gynecol Oncol; 2014 Mar; 132(3):703-8. PubMed ID: 24486603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
    Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
    Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
    Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
    Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
    Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
    J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear Y-Box-binding Protein-1 Expression Predicts Poor Clinical Outcome in Stage III Colorectal Cancer.
    Shiraiwa S; Kinugasa T; Kawahara A; Mizobe T; Ohchi T; Yuge K; Fujino S; Katagiri M; Shimomura S; Tajiri K; Sudo T; Kage M; Kuwano M; Akagi Y
    Anticancer Res; 2016 Jul; 36(7):3781-8. PubMed ID: 27354655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis.
    Lee CM; Lee RJ; Hammond E; Tsodikov A; Dodson M; Zempolich K; Gaffney DK
    Gynecol Oncol; 2004 Apr; 93(1):209-14. PubMed ID: 15047238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.
    Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S
    Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.
    Wu J; Lee C; Yokom D; Jiang H; Cheang MC; Yorida E; Turbin D; Berquin IM; Mertens PR; Iftner T; Gilks CB; Dunn SE
    Cancer Res; 2006 May; 66(9):4872-9. PubMed ID: 16651443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.
    Kersemaekers AM; Fleuren GJ; Kenter GG; Van den Broek LJ; Uljee SM; Hermans J; Van de Vijver MJ
    Clin Cancer Res; 1999 Mar; 5(3):577-86. PubMed ID: 10100709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer.
    Halle C; Lando M; Svendsrud DH; Clancy T; Holden M; Sundfør K; Kristensen GB; Holm R; Lyng H
    Clin Cancer Res; 2011 Aug; 17(16):5501-12. PubMed ID: 21737508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated expression of iASPP correlates with poor prognosis and chemoresistance/radioresistance in FIGO Ib1-IIa squamous cell cervical cancer.
    Cao L; Huang Q; He J; Lu J; Xiong Y
    Cell Tissue Res; 2013 May; 352(2):361-9. PubMed ID: 23420450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study.
    Kristensen GB; Holm R; Abeler VM; Tropé CG
    Cancer; 1996 Aug; 78(3):433-40. PubMed ID: 8697388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer.
    Pérez-Regadera J; Sánchez-Muñoz A; De-la-Cruz J; Ballestín C; Lora D; García-Martín R; Mendiola C; Alonso L; Alba E; Lanzós E
    Oncology; 2009; 76(2):133-41. PubMed ID: 19174612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.
    Lee CM; Shrieve DC; Zempolich KA; Lee RJ; Hammond E; Handrahan DL; Gaffney DK
    Gynecol Oncol; 2005 Nov; 99(2):415-21. PubMed ID: 16157365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
    Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
    Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.
    Noordhuis MG; Eijsink JJ; Ten Hoor KA; Roossink F; Hollema H; Arts HJ; Pras E; Maduro JH; Reyners AK; de Bock GH; Wisman GB; Schuuring E; van der Zee AG
    Clin Cancer Res; 2009 Dec; 15(23):7389-97. PubMed ID: 19920104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis.
    Ettl T; Stiegler C; Zeitler K; Agaimy A; Zenk J; Reichert TE; Gosau M; Kühnel T; Brockhoff G; Schwarz S
    Hum Pathol; 2012 Jun; 43(6):921-31. PubMed ID: 22154363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.
    Stratford AL; Habibi G; Astanehe A; Jiang H; Hu K; Park E; Shadeo A; Buys TP; Lam W; Pugh T; Marra M; Nielsen TO; Klinge U; Mertens PR; Aparicio S; Dunn SE
    Breast Cancer Res; 2007; 9(5):R61. PubMed ID: 17875215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expressions of receptor-binding cancer antigen expressed on SiSo cells, vascular endothelial growth factor, and matrix metalloproteinase-9 in cervical carcinoma and correlation thereof with the invasion and metastasis of the cancerous tissues].
    Liu R; Pu DM; Cheng YX; Yin L
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(19):1326-9. PubMed ID: 17727777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer.
    Ju XZ; Yang JM; Zhou XY; Li ZT; Wu XH
    Clin Cancer Res; 2008 Jan; 14(2):494-501. PubMed ID: 18223224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.